CD3-binding molecules capable of binding to human and non-human CD3
First Claim
1. A CD3-binding molecule comprising an antigen-binding fragment of an antibody, wherein said antigen-binding fragment comprises an antibody CD3-specific VL domain and an antibody CD3-specific VH domain, wherein said CD3-specific VL domain and said CD3-specific VH domain form an antigen-binding domain capable of immunospecifically binding to both an epitope of human CD3 and to an epitope of the CD3 of a non-human mammal, wherein:
- (I) said CD3-specific VL domain is selected from the group consisting of h mab2 VL-4 (SEQ ID NO;
22), h mab2 VL-6 (SEQ ID NO;
26), h-mab2 VL-7 (SEQ ID NO;
28), h-mab2 VL-8 (SEQ ID NO;
30), h-mab2 VL-9 (SEQ ID NO;
32), and h-mab2 VL-10 (SEQ ID NO;
34), and(II) said CD3-specific VH domain is selected from the group consisting of h-mab2 VH-1 (SEQ ID NO;
36), h-mab2 VH-2 (SEQ ID NO;
38), h-mab2 VH-3 (SEQ ID NO;
40), h-mab2 VH-4 (SEQ ID NO;
42), h-mab2 VH-5 (SEQ ID NO;
44), h-mab2 VH-6 (SEQ ID NO;
46), h-mab2 VH-7 (SEQ ID NO;
48), and h-mab2 VH-8 (SEQ ID NO;
50).
1 Assignment
0 Petitions
Accused Products
Abstract
CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey) are presented. Uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions are presented.
-
Citations
24 Claims
-
1. A CD3-binding molecule comprising an antigen-binding fragment of an antibody, wherein said antigen-binding fragment comprises an antibody CD3-specific VL domain and an antibody CD3-specific VH domain, wherein said CD3-specific VL domain and said CD3-specific VH domain form an antigen-binding domain capable of immunospecifically binding to both an epitope of human CD3 and to an epitope of the CD3 of a non-human mammal, wherein:
-
(I) said CD3-specific VL domain is selected from the group consisting of h mab2 VL-4 (SEQ ID NO;
22), h mab2 VL-6 (SEQ ID NO;
26), h-mab2 VL-7 (SEQ ID NO;
28), h-mab2 VL-8 (SEQ ID NO;
30), h-mab2 VL-9 (SEQ ID NO;
32), and h-mab2 VL-10 (SEQ ID NO;
34), and(II) said CD3-specific VH domain is selected from the group consisting of h-mab2 VH-1 (SEQ ID NO;
36), h-mab2 VH-2 (SEQ ID NO;
38), h-mab2 VH-3 (SEQ ID NO;
40), h-mab2 VH-4 (SEQ ID NO;
42), h-mab2 VH-5 (SEQ ID NO;
44), h-mab2 VH-6 (SEQ ID NO;
46), h-mab2 VH-7 (SEQ ID NO;
48), and h-mab2 VH-8 (SEQ ID NO;
50). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
Specification